Dementia Research Today
A plain-language tour of where Alzheimer's and dementia research stands now, from anti-amyloid drugs and blood tests to the 182 trials in the drug pipeline, and how to read the headlines.
Last reviewed: October 2026
For decades, dementia research produced more disappointments than breakthroughs. That has started to change. There are now medicines that modestly slow early Alzheimer's, blood tests that can detect Alzheimer's changes, and a busy pipeline of new ideas. There is still no cure. Here's a plain-language snapshot of where things stand.
The big shifts of the last few years
1. Drugs that slow early Alzheimer's
For the first time, medicines can change the course of the disease, not just ease symptoms. Lecanemab (Leqembi) and donanemab (Kisunla) are antibodies that clear amyloid plaques from the brain. In large trials they slowed decline by roughly a quarter to a third over about 18 months in people with mild cognitive impairment or mild dementia due to Alzheimer's. The benefit is modest, the infusions require regular visits and MRI monitoring, and they carry a risk of brain swelling or bleeding called ARIA. The National Institute on Aging describes them as treatments for early-stage disease, in people with confirmed amyloid.
2. Better, simpler tests
Alzheimer's changes used to be confirmed only with a PET scan, a spinal tap, or after death. Now blood tests that measure proteins such as p-tau217 can show whether Alzheimer's changes are likely, and some have been cleared by the FDA for use in people with symptoms. These tests make diagnosis faster and cheaper, and help researchers find the right people for trials. See Biomarkers.
3. Prevention is taken seriously
The 2024 Lancet Commission estimated that about 45% of dementia cases worldwide might be prevented or delayed by addressing 14 risk factors across life, such as high blood pressure, hearing loss, physical inactivity, smoking, high LDL cholesterol and untreated vision loss. Research is now testing lifestyle programs and medicines in people who don't yet have symptoms. See Reducing Dementia Risk: The 14 Risk Factors.
What's in the pipeline
Every year, researchers led by Dr. Jeffrey Cummings review every Alzheimer's drug trial registered on ClinicalTrials.gov. Their 2025 report counted 138 drugs being tested in 182 clinical trials, more than the year before. Some highlights from that review:
- About three-quarters of the drugs aim to change the disease itself, not just its symptoms.
- About a third are "repurposed" drugs, medicines already approved for other conditions (such as diabetes or blood pressure) being tested for Alzheimer's.
- Others aim to improve thinking or ease symptoms like agitation, sleep problems and depression.
Ideas being explored
- Tau-targeting drugs. Tau tangles track closely with symptoms, so many groups are trying to block tau or its spread. See Amyloid and Tau Explained.
- Inflammation and the immune system. The brain's immune cells may drive damage. See Inflammation and the Brain.
- Metabolic and vascular approaches. For example, GLP-1 drugs like semaglutide (two large trials of oral semaglutide did not slow Alzheimer's), and treatments that protect blood vessels.
- Infections and vaccines. Studies suggest the shingles vaccine may lower dementia risk. See Vaccines, Infections and Dementia Risk.
- Genetics. Research on APOE4, the strongest common risk gene, and on rare protective genes may point to new treatments. See Genetic Testing and APOE4.
- Combination treatments. Like heart disease or cancer, Alzheimer's may eventually be treated with several drugs together.
- Other dementias. Research is growing on Lewy Body Dementia, Frontotemporal Dementia and Vascular Dementia, which have fewer treatment options.
Reading research headlines
New "breakthroughs" make the news almost every week. A few quick questions help:
- Was it in people, or in mice or cells? Most early findings don't carry over to humans.
- Did it show cause, or just a link? Observational studies find associations, not proof.
- How big was the effect, and how many people?
- Has anyone repeated it?
Our daily updates try to explain new studies in this spirit.
How you can help research
Research depends on volunteers, including people without memory problems. You can:
- Join a clinical trial or study. Search ClinicalTrials.gov or the Alzheimer's Association's free TrialMatch service. See Joining a Clinical Trial.
- Join a registry, which lets researchers contact you about studies that fit.
- Volunteer at an Alzheimer's Disease Research Center (ADRC), funded by the NIH.
- Consider Brain Donation. Donated brains, from people with and without dementia, are among the most valuable resources researchers have.
The bottom line
Research is moving faster than ever. There's no cure yet, but there are now treatments that slow early Alzheimer's, better tests, a strong prevention message and a crowded pipeline of new ideas.
This article is for general information and is not a substitute for advice from your own doctor.
Sources
- Cummings JL et al. Alzheimer's disease drug development pipeline: 2025. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2025
- National Institute on Aging: How Is Alzheimer's Disease Treated?
- Alzheimer's Association: Research
- Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet, 2024
Not medical advice. This article is general information, not a diagnosis or treatment plan for any individual. Talk with a doctor about your situation.
Related articles
Ask a question
Have a question about memory, Alzheimer's, or caregiving? Email us at:
Open in my email app · Write in Gmail (opens in a new tab)
We may answer common questions in future updates (we won't share your name). We can't give personal medical advice; for urgent help call the Alzheimer's Association Helpline at 800-272-3900.